Table 4.
Summary of targeted SLNs for different cancer types in different stages of development. N.A.—not applicable.
| Lipid | Method | Drug | Targeting | Cancer | Phase | Ref |
|---|---|---|---|---|---|---|
| Compritol® | HSH | N.A. | Antibody against HR2 | BC | In vitro | [96] |
| Glyceryl stearate & Chol | Nanoprecipitation | PTX | Folic acid coated | LC | In vivo | [99] |
| SA and lecithin | HHPH | Satureja khuzistanica Essential Oil & folate-bound chitosan | Folic acid | BC | In vitro | [102] |
| Behenic acid | Coacervation | Methotrexate | Apoemimkin Chimera | GBM | In vivo | [110] |
| GMS and SA | SEE | Docetaxel | Angiopep-2 | GBM | In vivo | [109] |
| PA | SED | di-allyl-disulfide | RAGE antibody | BC | In vitro | [98] |
| DSPE | SED | Oxaliplatin | Folic acid | CRC | In vitro | [101] |
| GMS and TPGS | SEE | PTX and Curcumin | SA-folate | BC | In vitro | [100] |
| GMS, SPC, and Oda | Film-ultrasonic method | Docetaxel | HA-Te | BC | In vivo | [97] |
| Tristearin | SED | Irinotecan | Folic acid | CRC | In vivo | [111] |
| GMS | SEE | PTX and TSC | TAT | CC | In vivo | [106] |
| Trilaurin and TPGS | Microemulsion | DOX and SPIONs | Folic acid | CRC | In vivo | [105] |
| Glyceryl palmitostearate | Emulsification-solidification | PTX | Anti CD44v6 antibody | BC | In vitro | [112] |
| Stearyl amine | SEE | Gemcitabine | Mannose | LC | In vivo | [103] |
| Gelucire® 50/13 | Microemulsion | Methotrexate | Fucose | BC | In vivo | [104] |
| GMS | HHPH | PTX | Hyaluronic acid | CC & BC | In vivo | [113] |
| SA | SI (modified) | Resveratrol and Ferulic acid | Folic acid | CRC | In vitro | [114] |
| SA | Hot melted sonication | PTX | HP-β-CD | BC | In vivo | [115] |
| GMS and Compritol® | Hot melt-emulsification | Dox and Curcumin | Folic acid | BC | In vivo | [116] |
| Compritol®, tripalmitin, SA, and Chol | SEE | ETP | Melanotransferr-in antibody and Tamoxifen | GBM | In vitro | [108] |
| GMS | SEE | PTX | Wheat germ agglutinin | LC | In vivo | [117] |
| Compritol®, CL, and SA | Microemulsion | ETP | 83–14 MAb and AEGFR | GBM | In vitro | [107] |
| Behenic acid, tripalmitin, and cacao butter | SEE | Carmustine | Tamoxifen and Lectoferrin | GBM | In vitro | [118] |
| Tristearin & HSPC | SI | PTX | Lactoferrin | LC | In vitro | [39] |
| PA and Dynasan® | N.A. | Saquinavir | 83–14 MAb | GBM | In vitro | [119] |
| Compritol® 888 ATO and Precirol® ATO | Sonication of pre-emulsion | DTX | AS1411 anti-nucleolin aptamers | CRC | In vivo | [120] |
| Cetyl palmitate | Hot ultrasonication method | Mitoxantrone | Folate receptor | BC | In vitro | [121] |
Abbreviations: Lipid: Stearic Acid (SA), Glycerol Monostearate (GMS), Palmitic acid (PA), 1,2-distearoyl-sn-glycero-3-phosphoethanolamine (DSPE), DL-α-Tocopherol methoxypolyethylene glycol succinate (TPGS), Soy phosphatidylcholine (SPC), Octadecylamine (Oda), Cardiolipin (CL), Hydrogenated soya phosphatidylcholine (HSPC). Method: High Shear Homogenization (HSH), Hot High-Pressure Homogenization (HHPH), Solvent Emulsification-Evaporation (SEE), Solvent Emulsification-Diffusion (SED), Solvent Injection (SI). Drug: Paclitaxel (PTX), α-tocopherol succinate-cisplatin (TSC), Doxorubicin hydrochloride (DOX), Superparamagnetic iron oxide nanoparticles (SPIONs), Etoposide (ETP), Docetaxel (DTX). Cancer: Breast Cancer (BC), Lung Cancer (LC), Glioblastoma (GBM), Colorectal Cancer (CRC), Cervical Cancer (CC), Prostate Cancer (PC), Ovarian Cancer (OC).